Table 1 Clinicopathological features

Age (years)

66 (59–71)

Sex, male:female

107:43

Body mass index (kg/m²)

21.8 (19.8–24.1)

ASA-PS^a, 1:2:3

65:76:9

Tumor diameter (< 5:5–8: ≥ 8) (cm)

8:78:64

cT, 1b:2:3:4a:4b

1:10:40:94:5

cN, 0:1

37:113

cStage (TNM), II:III:IV

29:80:41

Approach, laparoscopic:robotic [da Vinci S/Si/Xi]

88:62 [8/8/46]

Type of resection, DG^b:(TG^c/PG^d):(TG/PG + splenectomy)

62:41:47

Extent of lymphadenectomy, D1 + :D2:D2 + 

7:138:5

Esophagogastric junctional cancer, n (%)

22 (14.7)

Conversion surgery, n (%)

41 (27.3)

Chemotherapy line

1 (1–1)

Chemotherapy regimen

 SP^e/SOX^f/FOLFOX^g/FP^h

114 [67/42/4/1]

 DCSⁱ

20

 XP^j/SOX + Trastuzumab

10 [5/5]

Others[FLOT^k ± Durvalumab/S1 + Paclitaxel iv^l,ip^m]

6 [4/2]

Chemotherapy cycle

2 (2–4)

ypStage (TNM), 0:I:II:III:IV

12:28:52:56:2

Histological response (primary lesion), grade 0:1a:1b:2:3

6:56:38:36:14

Grade ≥ 2, n(%)

50 (33.3)

Adjuvant chemotherapy (yes), n(%)

126 (84.0)

 S-1/Capecitabine

71 [69/2]

 SP/SOX/CapeOXⁿ/FP/FOLFOX

32 [9/20/1/1/1]

 DS^o/S-1 + Paclitaxel

7 [5/2]

 Docetaxel/nabPaclitaxel/CPT-11

6 [3/1/2]

 XP/SOX + Trastuzumab

3 [2/1]

 DCS

1

 CPT-11 + CDDP

1

 Others[FLOT ± Durvalumab/unknown]

5 [3/2]